Preliminary results of the phase II clinical trial of imatinib mesylate for advanced gastrointestinal stromal tumors in Japan

Gann Monographs on Cancer Research

Volumn 53, Issue , 2004, Pages 151-157

  Nishida, Toshirou ^a   Shirao, Kuniaki ^b   Yamao, Kenji ^c   Koseki, Masato ^d   Okamura, Takeshi ^e   Ohtsu, Atsushi ^f   Sugiyama, Toshiro ^g  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d National Hospital Organization   (Japan)

^e National Hospital Organization   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CGP 74588; DRUG METABOLITE; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASCITES; BLEEDING; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; JAPAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 23844463117     PISSN: 00720151     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (16)

1. Chen H, Hirota S, Isozaki K, Sun H, Ohashi A, Kinoshita K, O'Brien P, Kapusta L, Dardick I, Obayashi T, Okazaki T, Shinomura Y, Matsuzawa Y, Kitamura Y. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. Gut 2002; 51: 793-796.
2. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
3. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33: 466-477.
4. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
6. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988; 55: 185-192.
7. Giebel LB, Spritz RA. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci USA 1991; 88: 8696-8699.
8. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-434.
9. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. PDGFRα activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710.
10. Hirota S, Isozaki K, Moriyama Y, Kanakura Y, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Shinomura Y, Kitamura Y. Gain-of-function mutation of c-kit'm human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
11. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y. Gain-of-function mutations of platelet-derived Growth factor receptor alpha gene as another cause of human gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-667.
12. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
13. Kitamura Y, Hirota S, Nishida T. Gastrointestinal Stromal Tumor (GIST): A model for molecule-based diagnosis and treatment of solid tumors. Cancer Science 2003; 94: 315-320.
14. Nishida T, Hirota S, Matsuda H, Kitamura Y. Familial Gastrointestinal Stromal Tumors as a Cancer Syndrome. In: Kitamura Y, editor. In: Monograph on Cancer Research vol. 53. Tokyo: Japanese Cancer Association; 2004.
15. Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, Kanakura Y, Tanaka T, Takabayashi A, Matsuda H, Kitamura Y. Familial Gastrointestinal Stromal Tumors with Germ Line Mutation of the KIT gene. Nat Genet 1998; 19: 323-324.
16. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423.